225 related articles for article (PubMed ID: 25411961)
1. Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancer.
Fujiwara Y; Kobayashi T; Chayahara N; Imamura Y; Toyoda M; Kiyota N; Mukohara T; Nishiumi S; Azuma T; Yoshida M; Minami H
PLoS One; 2014; 9(11):e113259. PubMed ID: 25411961
[TBL] [Abstract][Full Text] [Related]
2. Ghrelin and leptin levels in cachectic patients with cancer of the digestive organs.
Takahashi M; Terashima M; Takagane A; Oyama K; Fujiwara H; Wakabayashi G
Int J Clin Oncol; 2009 Aug; 14(4):315-20. PubMed ID: 19705241
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer.
Dülger H; Alici S; Sekeroğlu MR; Erkog R; Ozbek H; Noyan T; Yavuz M
Int J Clin Pract; 2004 Jun; 58(6):545-9. PubMed ID: 15311551
[TBL] [Abstract][Full Text] [Related]
4. [Plasma concentration of leptin, neuropeptide Y and tumor necrosis factor alpha in patients with cancers, before and after radio- and chemotherapy].
Kowalczuk A; Wiecek A; Franek E; Kokot F
Pol Arch Med Wewn; 2001 Aug; 106(2):657-68. PubMed ID: 11926139
[TBL] [Abstract][Full Text] [Related]
5. Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD.
Ubhi BK; Cheng KK; Dong J; Janowitz T; Jodrell D; Tal-Singer R; MacNee W; Lomas DA; Riley JH; Griffin JL; Connor SC
Mol Biosyst; 2012 Oct; 8(12):3125-33. PubMed ID: 23051772
[TBL] [Abstract][Full Text] [Related]
6. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer.
Ramsey ML; Talbert E; Ahn D; Bekaii-Saab T; Badi N; Bloomston PM; Conwell DL; Cruz-Monserrate Z; Dillhoff M; Farren MR; Hinton A; Krishna SG; Lesinski GB; Mace T; Manilchuk A; Noonan A; Pawlik TM; Rajasekera PV; Schmidt C; Guttridge D; Hart PA
Pancreatology; 2019 Jan; 19(1):80-87. PubMed ID: 30497874
[TBL] [Abstract][Full Text] [Related]
7. Circulating leptin and inflammatory response in esophageal cancer, esophageal cancer-related cachexia-anorexia syndrome (CAS) and non-malignant CAS of the alimentary tract.
Diakowska D; Krzystek-Korpacka M; Markocka-Maczka K; Diakowski W; Matusiewicz M; Grabowski K
Cytokine; 2010 Aug; 51(2):132-7. PubMed ID: 20541434
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia.
Robinson DW; Eisenberg DF; Cella D; Zhao N; de Boer C; DeWitte M
J Support Oncol; 2008; 6(6):283-90. PubMed ID: 18724539
[TBL] [Abstract][Full Text] [Related]
9. Weight loss is not associated with hyperleptinemia in humans with pancreatic cancer.
Brown DR; Berkowitz DE; Breslow MJ
J Clin Endocrinol Metab; 2001 Jan; 86(1):162-6. PubMed ID: 11231995
[TBL] [Abstract][Full Text] [Related]
10. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia.
Barber MD; Fearon KC; Tisdale MJ; McMillan DC; Ross JA
Nutr Cancer; 2001; 40(2):118-24. PubMed ID: 11962246
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma.
Talar-Wojnarowska R; Gasiorowska A; Smolarz B; Romanowicz-Makowska H; Kulig A; Malecka-Panas E
Neoplasma; 2009; 56(1):56-62. PubMed ID: 19152246
[TBL] [Abstract][Full Text] [Related]
12. Emerging markers of cachexia predict survival in cancer patients.
Mondello P; Lacquaniti A; Mondello S; Bolignano D; Pitini V; Aloisi C; Buemi M
BMC Cancer; 2014 Nov; 14():828. PubMed ID: 25400234
[TBL] [Abstract][Full Text] [Related]
13. Analysis of inflammatory markers and hormones in old cancer patients: A descriptive study.
De Breucker S; Luce S; Njemini R; Bautmans I; Decoster L; Mets T; Pepersack T
Exp Gerontol; 2020 Feb; 130():110787. PubMed ID: 31794851
[TBL] [Abstract][Full Text] [Related]
14. A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients.
Fogelman DR; Morris J; Xiao L; Hassan M; Vadhan S; Overman M; Javle S; Shroff R; Varadhachary G; Wolff R; Vence L; Maitra A; Cleeland C; Wang XS
Support Care Cancer; 2017 Jun; 25(6):1809-1817. PubMed ID: 28111717
[TBL] [Abstract][Full Text] [Related]
15. The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia.
Bilir C; Engin H; Can M; Temi YB; Demirtas D
Med Oncol; 2015 Mar; 32(3):56. PubMed ID: 25638467
[TBL] [Abstract][Full Text] [Related]
16. Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients.
Sato H; Naito T; Ishida T; Kawakami J
Eur J Clin Pharmacol; 2016 Dec; 72(12):1463-1470. PubMed ID: 27566315
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning.
Han J; Meng Q; Shen L; Wu G
Lipids Health Dis; 2018 Jan; 17(1):14. PubMed ID: 29338749
[TBL] [Abstract][Full Text] [Related]
18. [Cytokines in experimental cancer cachexia].
Niu Q; Li T; Liu A
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):382-4. PubMed ID: 11810767
[TBL] [Abstract][Full Text] [Related]
19. Adipokines and systemic inflammation in weight-losing lung cancer patients.
Gulen ST; Karadag F; Karul AB; Kilicarslan N; Ceylan E; Kuman NK; Cildag O
Lung; 2012 Jun; 190(3):327-32. PubMed ID: 22246553
[TBL] [Abstract][Full Text] [Related]
20. Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels.
Miura T; Mitsunaga S; Ikeda M; Shimizu S; Ohno I; Takahashi H; Furuse J; Inagaki M; Higashi S; Kato H; Terao K; Ochiai A
Pancreas; 2015 Jul; 44(5):756-63. PubMed ID: 25931255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
